Business Wire

Leapmotor's 100,000th Mass-Produced Vehicle Rolls off the Line

28.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Today, Leapmotor's 100,000th mass-produced vehicle rolled off the line. On June 28, 2019, Leapmotor's first mass-produced vehicle, S01, rolled off the line. It took three years from S01 to C11 (the 100,000th mass-produced vehicle), realizing the leap from 0 to 100,000 in the field of intelligent EV. And it only took half a year to reach 100,000 vehicles from 50,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005686/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Leapmotor Reaches the Milestone of 100,000 Mass-produced Vehicles. Thanks for your support, the future can be expected. (Graphic: Business Wire)

Zhu Jiangming, the Founder and Chairman of Leapmotor, said in a thank-you letter that seven years witnessed Leapmotor's winning the trust of 100,000 users. In addition to gratitude, Leapmotor will go forward with more friends by adhering "guard against arrogance, and consistency in original aspiration". We will continue to make breakthroughs and innovation in the core technology field, and focus on the user-centered concept to keep moving with our users, thus delivering the finest smart mobility experience to all consumers.

After seven years of independent full-suite of R&D, the Leapmotor has ushered in a phenomenal development in 2022:

In March, the monthly delivery volume of Leapmotor vehicles exceeded the threshold of 10,000 units for the first time;
In April, launched the first mass-produced model with CTC technology in China - Released the integrated technology of battery chassis of Leapmotor intelligent power CTC;
In May, Leapmotor C01, the electric vehicle equipped with CTC technology without battery pack, launched a pre-sale, and the current order has reached 60000 units; at the same time, the delivery volume reached a new high in May, achieving a year-on-year growth of more than 200% for 14 consecutive months;
In June, the 100,000th mass-produced vehicle was off the production line.

Leapmotor independently controls the core technology. Since 2015, Leapmotor has established a short-term difficult but long-term correct route of full-suite of R&D, striving to build the core competitiveness of technological innovation, which has greatly enhanced Leapmotor's ability to resist external risks under uncertain factors.

Moreover, in order to cope with the uncertainty of the supply chain, Leapmotor also made a layout in advance, built the mechanism of multi supply enterprises and multi-regional planning, and effectively improved the ability of the supply chain to resist risks.

With the further innovation and improvement of Leapmotor product matrix, Leapmotor will brave winds and waves and continue to deliver the finest smart mobility experience to all consumers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tammy Hu
Email: hu_huiling@leapmotor.com
Phone number: +86-15724268142

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release

Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release

For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye